

Communications and Publications Division (CPD) of the IFCC Editor: Katherina Psarra, MSc, PhD IFCC Office, Via C. Farini, 81 20159 Milano, Italy E-mail: enews@ifcc.org



Nº 10 - October 2022





Left to right: Peter Baxter, Neil Mahon, Shaun Francis, Yogini Walli, Peter Nord

ADD-141949-GBL-EN

Article continued on next page 29

Ever wondered what it would be like to have a glimpse into your cardiovascular health? Tens of thousands of people in Canada not only wonder but proactively seek annual cardiovascular health assessments. In a world where cardiovascular diseases continue to be the leading killer globally, early and accurate health information could be game changers.

As a Canadian leader in annual cardiovascular health assessments, Medcan Health Management Inc. in Ontario, Canada just received prestigious recognition of Distinction for global healthcare excellence with the UNIVANTS of Healthcare Excellence program.

Medcan has been providing comprehensive annual health assessments (AHA) for the past 25 years, with an increase in clients annually. The cardiovascular portion of the health assessments had long included a stress test among many other factors. The stress test, however, was replaced during the COVID-19 pandemic with an objective blood biomarker. Ironically, the additive blood biomarker not only met the real-time requirements of assessing cardiovascular health but gave a glimpse into the future with respect to individual cardiovascular risk.

More specifically, an integrated clinical care team at Medcan replaced stress testing through implementation of high-sensitivity cardiac troponin testing (hs-cTnl) in order to enhance and improve identification of future risk of cardiovascular disease. Successful implementation has had significant impact across stakeholders, including their clients, clinicians, administration, and entire health system Within the first 6 months over 8,000 clients were screened as part of an annual CV health assessment, enabling identification of 204 clients as high risk for future cardiovascular events. Of those, 451 clients at moderate risk and 7,392 at low risk of future cardiovascular events. Detection enabled the commencement of appropriate preventative care and education across each level of risk. Additional benefits included a mitigated annualized savings of \$284,400 CND for Medcan and \$357,500 CND for the Canadian Healthcare System based on improved overall specificity. Finally, substantial time savings were realized for both clients and physicians, with average time saved of 38 minutes per client AHA and 45 minutes per day for each attending physician included in AHAs.

For their efforts in preventative medicine and innovative use of high-sensitivity cardiac troponin, this integrated clinical care team from Medcan was awarded the prestigious honor of distinction in association with the 2021 UNIVANTS of Healthcare Excellence Awards. Congratulations to Peter Nord, MD, Chief Medical officer at Medcan, Peter Baxter, BA, Director, Clinic and Corporate Application Services, Technology Services at Medcan, Shaun Francis, MBA, Chair and CEO of Medcan, Neil Mahon, MSc, PMP Chief Information Officer at Medcan, Yogini Walli, MSN Director, Clinic Services at Medcan.

To learn more and apply for the 2022 awards, please visit www.UNIVANTShce.com.

The deadline for 2022 applications is November 15, 2022.



ADD-141949-GBL-EN 30